Nordic Migraine Symposium 2019 TEVA

The United States (US) perspective on the use of anti-CGRP monoclonal antibodies mAbs was presented by Andrew Blumenfeld. He discussed the US guidelines and the rationale for them.

1. American Headache Society. Headache 2019;59:1-18.
2. Serrano D et al. Headache 2015;55:502-518.
3. Louter MA et al. Brain. 2013;136(Pt 11):3489-3496.
4. Schwedt TJ et al. J Headache Pain 2018;19:38.
5. Lanteri-Minet M et al. Pain 2005;118:319-326.
6. Rossi P et al. Headache 2005;45:561-570.
7. Buse DC et al. Headache 2019;59:306-338.
8. Spanou I et al. Headache 2019;59:1174-1186.
9. Walker CS et al. Ann Clin Transl Neurol 2016;3:309-310
10. Hay DL et al. Bri J Pharmacol 2018;175:3-17
11. Tough IR et al. Neurogastroenterol Motil 2018;30:e13454.
12. Stauffer VL et al. JAMA Neurol 2018;75:1080-1088.
13. Skljarevski V et al. Cephalalgia 2018;38:1442-1454.
14. Tepper SJ et al. Headache 2018;59:276-290.
15. Ferrari MD et al. Lancet 2019:1-11.

As co-author of the European Headache Federation (EHF) guideline on the use of anti-CGRP monoclonal antibodies (mAbs) for migraine prevention, Lars Bendtsen presented an overview of the scientific basis for the recommendations.

1. Sacco et al. J Headache Pain 2019.

Anna Sundholm presented an overview of all currently available acute and preventative treatments for the different migraine patients, and how to use them most effectively.

1. Steiner TJ et al. J Headache Pain 2011;12:419-426.
2. Steiner TJ et al. J Headache Pain 2019;20:24.
3. Sundholm A et al. Lakartidningen 2020;117. pii: FTS7.
4. http://www.huvudvarkssallskapet.se/ Accessed December 2019.
5. Silberstein SD. CNS Spectrums 2017;22:4-12.
6. Cameron C et al. Headache 2015;55 Suppl 4:221-235.
7. Ong JJY et al. Neurotherapeutics 2015;15:274-290.
8. Lipton RB et al. JAMA 200;284:2599-2605.
9. Sculpher M et al. Pharmacoeconomics 2002;20:91-100.
10. Ferrari MD et al. Lancet 2001;358:1668-1675.
11. Freitag F et al. Headache 2008;48: 341-354.
12. Brandes JL et al. Cephalalgia 2005;25: 735-742.
13. Lipton RB et al. Headache 2017;57:1026-1040.
14. Brandes JL et al. JAMA 2007;297:1443-1454.
15. ICHD-3. Cephalalgia 2018;38:1-211.
16. Evers S et al. Eur J Neurol 2009;16:968-981.
17. Silberstein S et al. Headache 2009;49:1153-1162.
18. Aurora SK et al. Headache 2011;51:1358-1373.
19. Tepper SJ et al. Lancet Neurol 2017;16: 425-434.
20. Ruff DD et al. Cephalalgia 2019;39:931-944.
21. Ferrari MD et al. Lancet 2019;394:1030-1040.
22. Tfelt-Hansen P et al. CNS Drugs 2012;26:375-382.

Migraine is a multifactorial disease and many patients search for alternative, non-pharmacological treatments to get better. Jakob Hansen presented an overview of the currently available non-pharmacological treatments and the evidence that exists for their effectiveness.

1. Tfelt-Hansen et al. CNS Drugs 2012;26:375-382.
2. Probyn K et al. BMJ Open 2017;7:e016670.
3. Chaibi A et al. J Headache Pain 2011;12:127-133.
4. Posadzki P et al. Cephalalgia 2011;31:964-970.
5. Linde K et al. Cochrane Database Syst Rev 2016;6:CD001218.
6. Diener H-C et al. Lancet Neurol 2006;5:310-316.
7. Von Luckner A et al. Headache 2018;58:199-209.

Mikko Kallela presented an overview of the efficacy and safety of the currently available anti-CGRP antibodies erenumab, fremanezumab, galcanezumab and eptinezumab.

1. Dodick DW et al. Cephalalgia 2019;39:1075-1085.
2. Goadsby PJ et al. N Engl J Med 2017;377:2123-2132.
3. Dodick DW et al. Cephalalgia 2018;38:1026-37.
4. Tepper S et al. Lancet Neurol 2017;16:425-434.
5. Dodick DW et al. JAMA 2018;319:1999-2008.
6. Silberstein SD et al. N Engl J Med 2017;377:2113-2122.
7. Stauffer VL et al. JAMA Neurol 2018;75:1080-1088.
8. Skljarevski V et al. Cephalalgia 2018;38:1442-1454.
9. Detke HC et al. Neurology 2018;91:e2211-e21.
10. Saper J et al. Cephalalgia 2017;37:337.
11. Ashina M et al. Cephalalgia 2019;39:1455-1464.
12. Ning X et al. Neurology 2019;92(15 Supplement).
13. Ferrari MD et al. Lancet 2019;394:1030-1040.

Prof. Lars Edvinsson showed the audience how calcitonin gene-related peptide (CGRP) gradually became one of the most important molecules in primary headaches. From its discovery in the early 1980s to its role as an important target for novel specific anti-migraine drugs.

1. Edvinsson L et al. Brain Res Rev 2005;48:438-468.
2. Markowitz S et al. J Neurosci 1987;7:4129-4136.
3. Goldstein DJ et al. Cephalalgia 1997;17:785-790.
4. Amara SG et al. Nature 1982;298:240-244.
5. Rosenfeld MG et al. Science 1984;225:1315-1320.
6. Edvinsson L et al. Trends Neurosci 1985;8:126-131.
7. Uddman R et al. Neurosci Lett 1985;62:131-136.
8. McCulloch J et al. PNAS 1986;83:5731-5735.
9. Edvinsson L et al. Pharmacol Toxicol 2001;86:65-73.
10. Edvinsson L et al. Br J Pharmacol 1990;100:312-318.
11. Edvinsson L et al. Cephalalgia 1995;15:272-276.
12. Goadsby PJ et al. Ann Neurol 1988;23:193-196.
13. Edvinsson L et al. Neurotherapeutics 2010;7:164-175.
14. Goadsby PJ et al. Ann Neurol 1993;33:48-56.
15. Edvinsson L et al. Nat Rev Neurol 2018;14:338-350.
16. Liu Y et al. Cephalalgia 2009;29:935-948.
17. Eftekhari S et al. Brain Res 2015;1600:93-109.
18. Edvinsson L et al. Br J Clin Pharm 2015;80:193-199.